These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23578667)

  • 1. Longitudinal restriction spectrum imaging is resistant to pseudoresponse in patients with high-grade gliomas treated with bevacizumab.
    Kothari P; White NS; Farid N; Chung R; Kuperman JM; Girard HM; Shankaranarayanan A; Kesari S; McDonald CR; Dale AM
    AJNR Am J Neuroradiol; 2013 Sep; 34(9):1752-1757. PubMed ID: 23578667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.
    McDonald CR; Delfanti RL; Krishnan AP; Leyden KM; Hattangadi-Gluth JA; Seibert TM; Karunamuni R; Elbe P; Kuperman JM; Bartsch H; Piccioni DE; White NS; Dale AM; Farid N
    Neuro Oncol; 2016 Nov; 18(11):1579-1590. PubMed ID: 27106406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma.
    Krishnan AP; Karunamuni R; Leyden KM; Seibert TM; Delfanti RL; Kuperman JM; Bartsch H; Elbe P; Srikant A; Dale AM; Kesari S; Piccioni DE; Hattangadi-Gluth JA; Farid N; McDonald CR; White NS
    AJNR Am J Neuroradiol; 2017 May; 38(5):882-889. PubMed ID: 28279985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria).
    Farid N; Almeida-Freitas DB; White NS; McDonald CR; Kuperman JM; Almutairi AA; Muller KA; VandenBerg SR; Kesari S; Dale AM
    J Neurooncol; 2014 Dec; 120(3):539-46. PubMed ID: 25135423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab.
    Ellingson BM; Cloughesy TF; Lai A; Nghiemphu PL; Pope WB
    Magn Reson Med; 2012 Jan; 67(1):237-45. PubMed ID: 21702063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved conspicuity and delineation of high-grade primary and metastatic brain tumors using "restriction spectrum imaging": quantitative comparison with high B-value DWI and ADC.
    White NS; McDonald CR; Farid N; Kuperman JM; Kesari S; Dale AM
    AJNR Am J Neuroradiol; 2013 May; 34(5):958-64, S1. PubMed ID: 23139079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker.
    Jain R; Scarpace LM; Ellika S; Torcuator R; Schultz LR; Hearshen D; Mikkelsen T
    J Neurooncol; 2010 Feb; 96(3):423-31. PubMed ID: 19859666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI assessment of relapsed glioblastoma during treatment with bevacizumab: volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression--a pilot study.
    Pichler J; Pachinger C; Pelz M; Kleiser R
    Eur J Radiol; 2013 May; 82(5):e240-5. PubMed ID: 23399039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early response evaluation for recurrent high grade gliomas treated with bevacizumab: a volumetric analysis using diffusion-weighted imaging.
    Hwang EJ; Cha Y; Lee AL; Yun TJ; Kim TM; Park CK; Kim JH; Sohn CH; Park SH; Kim IH; Heo DS; Lee SH; Choi SH
    J Neurooncol; 2013 May; 112(3):427-35. PubMed ID: 23417358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse.
    Auer TA; Breit HC; Marini F; Renovanz M; Ringel F; Sommer CJ; Brockmann MA; Tanyildizi Y
    J Neuroradiol; 2019 Feb; 46(1):36-43. PubMed ID: 29733920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients.
    Rieger J; Bähr O; Müller K; Franz K; Steinbach J; Hattingen E
    J Neurooncol; 2010 Aug; 99(1):49-56. PubMed ID: 20035366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment.
    Yamasaki F; Kurisu K; Aoki T; Yamanaka M; Kajiwara Y; Watanabe Y; Takayasu T; Akiyama Y; Sugiyama K
    Eur J Radiol; 2012 Oct; 81(10):2805-10. PubMed ID: 22100373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.
    Artzi M; Bokstein F; Blumenthal DT; Aizenstein O; Liberman G; Corn BW; Ben Bashat D
    Eur J Radiol; 2014 Jul; 83(7):1250-1256. PubMed ID: 24809637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma.
    LaViolette PS; Mickevicius NJ; Cochran EJ; Rand SD; Connelly J; Bovi JA; Malkin MG; Mueller WM; Schmainda KM
    Neuro Oncol; 2014 Dec; 16(12):1599-606. PubMed ID: 25059209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival.
    Chen C; Huang R; MacLean A; Muzikansky A; Mukundan S; Wen PY; Norden AD
    J Neurooncol; 2013 Nov; 115(2):267-76. PubMed ID: 23974656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphomas and glioblastomas: differences in the apparent diffusion coefficient evaluated with high b-value diffusion-weighted magnetic resonance imaging at 3T.
    Doskaliyev A; Yamasaki F; Ohtaki M; Kajiwara Y; Takeshima Y; Watanabe Y; Takayasu T; Amatya VJ; Akiyama Y; Sugiyama K; Kurisu K
    Eur J Radiol; 2012 Feb; 81(2):339-44. PubMed ID: 21129872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Edge Contrast of the FLAIR Hyperintense Region Predicts Survival in Patients with High-Grade Gliomas following Treatment with Bevacizumab.
    Bahrami N; Piccioni D; Karunamuni R; Chang YH; White N; Delfanti R; Seibert TM; Hattangadi-Gluth JA; Dale A; Farid N; McDonald CR
    AJNR Am J Neuroradiol; 2018 Jun; 39(6):1017-1024. PubMed ID: 29622553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma.
    Nowosielski M; Recheis W; Goebel G; Güler O; Tinkhauser G; Kostron H; Schocke M; Gotwald T; Stockhammer G; Hutterer M
    Neuroradiology; 2011 Apr; 53(4):291-302. PubMed ID: 21125399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma.
    Gupta A; Young RJ; Karimi S; Sood S; Zhang Z; Mo Q; Gutin PH; Holodny AI; Lassman AB
    AJNR Am J Neuroradiol; 2011 Aug; 32(7):1301-1306. PubMed ID: 21596805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.
    Ellingson BM; Cloughesy TF; Lai A; Mischel PS; Nghiemphu PL; Lalezari S; Schmainda KM; Pope WB
    Neuro Oncol; 2011 Oct; 13(10):1151-61. PubMed ID: 21856685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.